Chengdu Origen Biotechnology Co., Ltd.
Clinical trials sponsored by Chengdu Origen Biotechnology Co., Ltd., explained in plain language.
-
One-Shot gene therapy could replace monthly eye injections for vision loss
Disease control OngoingThis is an early-stage safety study testing a new gene therapy called KH658 for people with 'wet' age-related macular degeneration (AMD), a leading cause of vision loss. The therapy is designed as a one-time injection into the eye to deliver a gene that helps block the abnormal b…
Phase: PHASE1 • Sponsor: Chengdu Origen Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
One-Shot gene therapy aims to replace monthly eye injections for vision loss
Disease control OngoingThis early-stage study is testing the safety of a new gene therapy called KH631 for people with 'wet' age-related macular degeneration (AMD), a leading cause of vision loss. The therapy is designed as a one-time injection into the eye to help the body block a protein that causes …
Phase: PHASE1 • Sponsor: Chengdu Origen Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC